Parkinson-HMR

The database includes the raw data of the article “Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson’s disease” (doi.org/10.1016/j.nut.2019.04.006). The aim of this study was to evaluate the effects of chronic treatment with lignan 7-hydroxymatairesinol (HMR/lignan) on Parkinson’s disease-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine (6-OHDA) model. The database contains the data obtained by the following evaluations: a) immunohistochemical analysis of the extent of nigrostriatal lesion, b) motor performance assessment by cylinder test (at baseline and after 28days), apomorphine-induced rotation test, c) immunohistochemical analysis of neuroinflammatory response - involving microglia and astrocytes - in the substantia nigra pars compacta, investigating both cell activation and polarization.

chronic treatment with HMR/lignan was able to slow down the progression of degeneration of striatal dopaminergic terminals in a rat model of PD, with a consequent improvement in motor performance. Nevertheless, the anti-inflammatory effect of HMR/lignan observed in SNc was not sufficient to protect dopaminergic cells bodies. These results suggest intriguing properties of HMR/lignan at neuroprotective and symptomatic levels in the context of PD.